Please login to the form below

Not currently logged in
Email:
Password:

Pomalyst

This page shows the latest Pomalyst news and features for those working in and with pharma, biotech and healthcare.

FDA ‘names and shames’ generic-blocking pharma companies

FDA ‘names and shames’ generic-blocking pharma companies

Pomalyst, followed by Actelion with 26 inquiries mainly for pulmonary artery hypertension drugs Tracleer and Opsumit.

Latest news

  • Celgene’s triple multiple myeloma therapy clears phase III trial Celgene’s triple multiple myeloma therapy clears phase III trial

    Its presence in the field is showing no signs of wavering either, following new data from a pivotal phase III trial of Pomalyst whose results are looking good for Celgene. ... Pomalyst (pomalidomide) - Celgene’s second biggest earner - brought in

  • Celgene reaches $9bn agreement to buy Juno Celgene reaches $9bn agreement to buy Juno

    Celgene is already a big player in blood cancers and haematology with Revlimid (lenalidomide), Pomalyst (pomalidomide) and Thalomid (thalidomide), and buying Juno keeps it in the running for a new generation

  • BMS' Opdivo and Yervoy ace kidney cancer trial BMS' Opdivo and Yervoy ace kidney cancer trial

    The FDA is concerned about the risk associated with combining PD-1/PD-L1 inhibitors such as Keytruda and Opdivo with Celgene's Pomalyst (pomalidomide) or Revlimid (lenalidomide), two widely-used

  • FDA halts third Merck myeloma trial after patient deaths FDA halts third Merck myeloma trial after patient deaths

    More patients taking Merck's drug died than those getting other treatment in the three trials, which all involved combinations of Keytruda with Celgene's Pomalyst (pomalidomide) and Revlimid (lenalidomide), two ... KEYNOTE-183 is testing Pomalyst and

  • Merck suspends two Keytruda trials after patient deaths Merck suspends two Keytruda trials after patient deaths

    Merck suspends two Keytruda trials after patient deaths. Investigators to look at Keytruda with Pomalyst and Revlimid. ... The two trials - KEYNOTE-183 and KEYNOTE-185 - involve combinations of Keytruda with Celgene's Pomalyst (pomalidomide) and Revlimid

More from news
Approximately 3 fully matching, plus 12 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics